Project Grant R44CA295168
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$674K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77054, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $650,671 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Marker Therapeutics Inc., a self-certified small disadvantaged biotechnology company. The grant supports the development and clinical evaluation of a binary T-cell therapy strategy to treat pancreatic cancer. The project aims to create two T-cell products: 1) Decoy-producing T-cells that can alter the tumor microenvironment to be more supportive of subsequent...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) totaling $107,948 aims to develop an immunotherapy approach for treating pancreatic cancer using micro-RNA-29a. The key objectives are to: 1) Alter the differentiation of terminally exhausted T cells to a progenitor and memory-like phenotype that is responsive to immune checkpoint blockade therapy, and 2) Determine the contribution of myeloid-derived TNF-TNFR2 signaling to T...
This $351,131 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at the University of Miami to disrupt the interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) in order to overcome resistance to chemoimmunotherapy in pancreatic cancer. The key objectives are to: 1) Mechanistically dissect the signaling and spatial interactions between MDSC-derived transmembrane TNF and...
This $294,962 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the clinical testing of a novel immunotherapeutic approach for treating metastatic, unresectable pancreatic ductal adenocarcinoma (PDAC) patients. The approach combines a Listeria-based bacteria delivery system that selectively targets tumors to express the tetanus toxoid (TT) antigen, with the chemotherapeutic agent gemcitabine. Preliminary data in mouse models has shown...
This $578,998 Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC). The key objectives are to:
Determine the mechanisms by which the cancer-specific Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins through advanced glycoproteomics analysis in mouse models and clinical samples.
Validate the role...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $338,828 to support research on improving the efficacy of platinum-based cancer drugs, such as oxaliplatin, for treating pancreatic cancer. The key objectives are to investigate the potential of a novel polynuclear platinum complex (triplatin) to selectively target and accumulate in pancreatic tumors expressing high levels of the glycosaminoglycan...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $421,685 to The University of Texas Southwestern Medical Center to investigate the therapeutic potential of inhibiting the protein pleiotrophin (PTN) to combat pancreatic cancer metastasis. The 2-year project aims to determine if blocking PTN, which is associated with pancreatic cancer progression, can reduce metastasis and enhance the effectiveness of chemotherapy and...
The National Cancer Institute (NCI) awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization, to conduct preclinical research on targeting cellular senescence in pancreatic ductal adenocarcinoma (PDAC). The grant aims to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its ability to improve the efficacy of standard-of-care...
This $627,272 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to optimize the efficacy of chimeric antigen receptor (CAR) T-cell therapy against pancreatic tumors. The primary goal is to develop engineered "velocity receptor" (VR) CAR T-cells that enhance migration speed and tumor infiltration compared to conventional CAR T-cells. The researchers at The Johns Hopkins University will test various VR...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for research aimed at developing an innovative protein drug called PROAGIO to simultaneously target cancer-associated fibroblasts (CAFs) and abnormal tumor blood vessels in pancreatic ductal adenocarcinoma (PDAC). The $590,094 award to the University of Alabama at Birmingham (UAB) will support a Phase I clinical trial to evaluate the safety, pharmacokinetics, and preliminary...